← Patent-cliff monitor Loss of exclusivity January 2036 latest FDA-listed patent expiry
Company Hikma → View the full company profile on CliffBio Drug detail Brand name COMBOGESIC IV Active ingredient ACETAMINOPHEN; IBUPROFEN SODIUM Strength 1GM/100ML (10MG/ML);EQ 300MG BASE/100ML (EQ 3MG BASE/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 11213498 January 2036 product 12083087 July 2035 use U-3745 11389416 July 2035 product 12220392 October 2031 use U-4307 11446266 October 2031 use U-3745 11896567 October 2031 use U-3745
Regulatory exclusivity Code Expires NP October 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.